Skip to main content
Erschienen in: Clinical Autonomic Research 3/2008

01.06.2008 | RESEARCH ARTICLE

Cardiac sympathetic hypo-innervation in familial dysautonomia

verfasst von: David S. Goldstein, MD, PhD, Basil Eldadah, MD, PhD, Yehonatan Sharabi, MD, Felicia B. Axelrod, MD

Erschienen in: Clinical Autonomic Research | Ausgabe 3/2008

Einloggen, um Zugang zu erhalten

Abstract

Objective

Familial dysautonomia (FD) involves incomplete development of the sympathetic nervous system. Whether such loss extends to sympathetic innervation of the heart has been unknown. This study used 6-[18F]fluorodopamine neuroimaging to assess cardiac sympathetic innervation and function in FD.

Methods

Six adult FD patients underwent thoracic PET scanning for 30 minutes after i.v. 6-[18F]fluorodopamine injection, as did healthy volunteers without (N = 21) or with (N = 10) pre-treatment by desipramine, which interferes with neuronal uptake and thereby simulates effects of noradrenergic denervation. Effective rate constants for uptake and loss were calculated using a single compartment pharmacokinetic model.

Results

FD patients had decreased uptake and accelerated loss of 6-[18F]fluorodopamine-derived radioactivity in the interventricular myocardial septum (P = 0.009, P = 0.05) and ventricular free wall (P = 0.007, P < 0.001), compared to untreated controls. Desipramine-treated subjects had decreased uptake but normal loss of 6-[18F]fluorodopamine-derived radioactivity.

Conclusions

FD involves cardiac noradrenergic hypo-innervation. Since accelerated loss of 6-[18F]fluorodopamine-derived radioactivity cannot be explained by decreased neuronal uptake alone, FD may also involve augmented NE loss from extant terminals.
Literatur
2.
Zurück zum Zitat Axelrod FB, Goldberg JD, Ye XY, Maayan C (2002) Survival in familial dysautonomia: impact of early intervention. J Pediatr 141:518–523PubMedCrossRef Axelrod FB, Goldberg JD, Ye XY, Maayan C (2002) Survival in familial dysautonomia: impact of early intervention. J Pediatr 141:518–523PubMedCrossRef
3.
Zurück zum Zitat Close P, Hawkes N, Cornez I, Creppe C, Lambert CA, Rogister B, Siebenlist U, Merville MP, Slaugenhaupt SA, Bours V, Svejstrup JQ, Chariot A (2006) Transcription impairment and cell migration defects in elongator-depleted cells: implication for familial dysautonomia. Mol Cell 22:521–531PubMedCrossRef Close P, Hawkes N, Cornez I, Creppe C, Lambert CA, Rogister B, Siebenlist U, Merville MP, Slaugenhaupt SA, Bours V, Svejstrup JQ, Chariot A (2006) Transcription impairment and cell migration defects in elongator-depleted cells: implication for familial dysautonomia. Mol Cell 22:521–531PubMedCrossRef
4.
Zurück zum Zitat Freedman LS, Ebstein RP, Goldstein M, Axelrod FB, Dancis J (1975) Serum dopamine-beta-hydroxylase in familial dysautonomia. J Lab Clin Med 85:1008–1012PubMed Freedman LS, Ebstein RP, Goldstein M, Axelrod FB, Dancis J (1975) Serum dopamine-beta-hydroxylase in familial dysautonomia. J Lab Clin Med 85:1008–1012PubMed
5.
Zurück zum Zitat Glickstein JS, Axelrod FB, Friedman D (1999) Electrocardiographic repolarization abnormalities in familial dysautonomia: an indicator of cardiac autonomic dysfunction. Clin Auton Res 9:109–112PubMedCrossRef Glickstein JS, Axelrod FB, Friedman D (1999) Electrocardiographic repolarization abnormalities in familial dysautonomia: an indicator of cardiac autonomic dysfunction. Clin Auton Res 9:109–112PubMedCrossRef
6.
Zurück zum Zitat Gold-von Simson G, Rutkowski M, Berlin D, Axelrod FB (2005) Pacemakers in patients with familial dysautonomia–a review of experience with 20 patients. Clin Auton Res 15:15–20PubMedCrossRef Gold-von Simson G, Rutkowski M, Berlin D, Axelrod FB (2005) Pacemakers in patients with familial dysautonomia–a review of experience with 20 patients. Clin Auton Res 15:15–20PubMedCrossRef
7.
Zurück zum Zitat Goldstein DS, Eisenhofer G, Dunn BB, Armando I, Lenders J, Grossman E, Holmes C, Kirk KL, Bacharach S, Adams R, Herscovitch P, Kopin IJ (1993) Positron emission tomographic imaging of cardiac sympathetic innervation using 6-[18F]fluorodopamine: initial findings in humans. J Am Coll Cardiol 22:1961–1971PubMedCrossRef Goldstein DS, Eisenhofer G, Dunn BB, Armando I, Lenders J, Grossman E, Holmes C, Kirk KL, Bacharach S, Adams R, Herscovitch P, Kopin IJ (1993) Positron emission tomographic imaging of cardiac sympathetic innervation using 6-[18F]fluorodopamine: initial findings in humans. J Am Coll Cardiol 22:1961–1971PubMedCrossRef
8.
Zurück zum Zitat Goldstein DS, Grossman E, Tamrat M, Chang PC, Eisenhofer G, Bacher J, Kirk KL, Bacharach S, Kopin IJ (1991) Positron emission imaging of cardiac sympathetic innervation and function using 18F-6-fluorodopamine: effects of chemical sympathectomy by 6-hydroxydopamine. J Hypertens 9:417–423PubMedCrossRef Goldstein DS, Grossman E, Tamrat M, Chang PC, Eisenhofer G, Bacher J, Kirk KL, Bacharach S, Kopin IJ (1991) Positron emission imaging of cardiac sympathetic innervation and function using 18F-6-fluorodopamine: effects of chemical sympathectomy by 6-hydroxydopamine. J Hypertens 9:417–423PubMedCrossRef
9.
Zurück zum Zitat Goldstein DS, Holmes C, Li ST, Bruce S, Metman LV, Cannon RO 3rd (2000) Cardiac sympathetic denervation in Parkinson disease. Ann Intern Med 133:338–347PubMed Goldstein DS, Holmes C, Li ST, Bruce S, Metman LV, Cannon RO 3rd (2000) Cardiac sympathetic denervation in Parkinson disease. Ann Intern Med 133:338–347PubMed
10.
Zurück zum Zitat Goldstein DS, Holmes C, Stuhlmuller JE, Lenders JWM, Kopin IJ (1997) 6-[18F]Fluorodopamine positron emission tomographic scanning in the assessment of cardiac sympathoneural function–studies in normal humans. Clin Auton Res 7:17–29PubMedCrossRef Goldstein DS, Holmes C, Stuhlmuller JE, Lenders JWM, Kopin IJ (1997) 6-[18F]Fluorodopamine positron emission tomographic scanning in the assessment of cardiac sympathoneural function–studies in normal humans. Clin Auton Res 7:17–29PubMedCrossRef
11.
Zurück zum Zitat Goldstein DS, Katzper M, Linares OA, Kopin IJ (2002) Kinetic model for the fate of the sympathoneural imaging agent 6-[18F]fluorodopamine in the human heart: a novel means to assess cardiac sympathetic neuronal function. Naunyn-Schmiedeberg’s Arch Pharmacol 365:38–49CrossRef Goldstein DS, Katzper M, Linares OA, Kopin IJ (2002) Kinetic model for the fate of the sympathoneural imaging agent 6-[18F]fluorodopamine in the human heart: a novel means to assess cardiac sympathetic neuronal function. Naunyn-Schmiedeberg’s Arch Pharmacol 365:38–49CrossRef
12.
Zurück zum Zitat Goodall MC, Gitlow SE, Alton H (1971) Decreased noradrenaline (norepinephrine) synthesis in familial dysautonomia. J Clin Invest 50:2734–2740PubMedCrossRef Goodall MC, Gitlow SE, Alton H (1971) Decreased noradrenaline (norepinephrine) synthesis in familial dysautonomia. J Clin Invest 50:2734–2740PubMedCrossRef
13.
Zurück zum Zitat Kashihara K, Ohno M, Kawada S, Okumura Y (2006) Reduced cardiac uptake and enhanced washout of 123I-MIBG in pure autonomic failure occurs conjointly with Parkinson’s disease and dementia with Lewy bodies. J Nucl Med 47:1099–1101PubMed Kashihara K, Ohno M, Kawada S, Okumura Y (2006) Reduced cardiac uptake and enhanced washout of 123I-MIBG in pure autonomic failure occurs conjointly with Parkinson’s disease and dementia with Lewy bodies. J Nucl Med 47:1099–1101PubMed
14.
Zurück zum Zitat Pearson J, Brandeis L, Goldstein M (1979) Tyrosine hydroxylase immunoreactivity in familial dysautonomia. Science 206:71–72PubMedCrossRef Pearson J, Brandeis L, Goldstein M (1979) Tyrosine hydroxylase immunoreactivity in familial dysautonomia. Science 206:71–72PubMedCrossRef
15.
Zurück zum Zitat Pearson J, Dancis J, Axelrod F, Grover N (1975) The sural nerve in familial dysautonomia. J Neuropathol Exp Neurol 34:413–424PubMedCrossRef Pearson J, Dancis J, Axelrod F, Grover N (1975) The sural nerve in familial dysautonomia. J Neuropathol Exp Neurol 34:413–424PubMedCrossRef
16.
Zurück zum Zitat Pearson J, Gallo G, Gluck M, Axelrod F (1980) Renal disease in familial dysautonomia. Kidney Int 17:102–112PubMedCrossRef Pearson J, Gallo G, Gluck M, Axelrod F (1980) Renal disease in familial dysautonomia. Kidney Int 17:102–112PubMedCrossRef
17.
Zurück zum Zitat Pearson J, Pytel BA (1978) Quantitative studies of sympathetic ganglia and spinal cord intermedio-lateral gray columns in familial dysautonomia. J Neurol Sci 39:47–59PubMedCrossRef Pearson J, Pytel BA (1978) Quantitative studies of sympathetic ganglia and spinal cord intermedio-lateral gray columns in familial dysautonomia. J Neurol Sci 39:47–59PubMedCrossRef
18.
Zurück zum Zitat Rotstein A, Charrow J, Deal BJ (2007) Documented transient third-degree atrioventricular block and asystole in a child with familial dysautonomia. Pediatr Cardiol Rotstein A, Charrow J, Deal BJ (2007) Documented transient third-degree atrioventricular block and asystole in a child with familial dysautonomia. Pediatr Cardiol
19.
Zurück zum Zitat Slaugenhaupt SA, Blumenfeld A, Gill SP, Leyne M, Mull J, Cuajungco MP, Liebert CB, Chadwick B, Idelson M, Reznik L, Robbins C, Makalowska I, Brownstein M, Krappmann D, Scheidereit C, Maayan C, Axelrod FB, Gusella JF (2001) Tissue-specific expression of a splicing mutation in the IKBKAP gene causes familial dysautonomia. Am J Hum Genet 68:598–605PubMedCrossRef Slaugenhaupt SA, Blumenfeld A, Gill SP, Leyne M, Mull J, Cuajungco MP, Liebert CB, Chadwick B, Idelson M, Reznik L, Robbins C, Makalowska I, Brownstein M, Krappmann D, Scheidereit C, Maayan C, Axelrod FB, Gusella JF (2001) Tissue-specific expression of a splicing mutation in the IKBKAP gene causes familial dysautonomia. Am J Hum Genet 68:598–605PubMedCrossRef
20.
Zurück zum Zitat Slaugenhaupt SA, Mull J, Leyne M, Cuajungco MP, Gill SP, Hims MM, Quintero F, Axelrod FB, Gusella JF (2004) Rescue of a human mRNA splicing defect by the plant cytokinin kinetin. Hum Mol Genet 13:429–436PubMedCrossRef Slaugenhaupt SA, Mull J, Leyne M, Cuajungco MP, Gill SP, Hims MM, Quintero F, Axelrod FB, Gusella JF (2004) Rescue of a human mRNA splicing defect by the plant cytokinin kinetin. Hum Mol Genet 13:429–436PubMedCrossRef
21.
Zurück zum Zitat Smith AA, Taylor T, Wortis B (1963) Abnormal catechol amine metabolism in familial dysautonomia. N Engl J Med 268:705–707PubMed Smith AA, Taylor T, Wortis B (1963) Abnormal catechol amine metabolism in familial dysautonomia. N Engl J Med 268:705–707PubMed
22.
Zurück zum Zitat Taki J, Nakajima K, Hwang EH, Matsunari I, Komai K, Yoshita M, Sakajiri K, Tonami N (2000) Peripheral sympathetic dysfunction in patients with Parkinson’s disease without autonomic failure is heart selective and disease specific. Eur J Nucl Med 27:566–573PubMedCrossRef Taki J, Nakajima K, Hwang EH, Matsunari I, Komai K, Yoshita M, Sakajiri K, Tonami N (2000) Peripheral sympathetic dysfunction in patients with Parkinson’s disease without autonomic failure is heart selective and disease specific. Eur J Nucl Med 27:566–573PubMedCrossRef
23.
Zurück zum Zitat Weinshilboum RM, Axelrod J (1971) Reduced plasma dopamine-beta-hydroxylase activity in familial dysautonomia. N Engl J Med 285:938–942PubMed Weinshilboum RM, Axelrod J (1971) Reduced plasma dopamine-beta-hydroxylase activity in familial dysautonomia. N Engl J Med 285:938–942PubMed
24.
Zurück zum Zitat Ziegler MG, Lake CR, Kopin IJ (1976) Deficient sympathetic nervous response in familial dysautonomia. N Engl J Med 294:630–633PubMed Ziegler MG, Lake CR, Kopin IJ (1976) Deficient sympathetic nervous response in familial dysautonomia. N Engl J Med 294:630–633PubMed
Metadaten
Titel
Cardiac sympathetic hypo-innervation in familial dysautonomia
verfasst von
David S. Goldstein, MD, PhD
Basil Eldadah, MD, PhD
Yehonatan Sharabi, MD
Felicia B. Axelrod, MD
Publikationsdatum
01.06.2008
Verlag
D. Steinkopff-Verlag
Erschienen in
Clinical Autonomic Research / Ausgabe 3/2008
Print ISSN: 0959-9851
Elektronische ISSN: 1619-1560
DOI
https://doi.org/10.1007/s10286-008-0464-1

Weitere Artikel der Ausgabe 3/2008

Clinical Autonomic Research 3/2008 Zur Ausgabe